Sporadic and familial nonautoimmune hyperthyroidism are very rarely occurring diseases. Within the last years constitutively activating TSH receptor mutations were identified as one possible pathomechanism. Except for S281N in the extracellular N-terminal domain, all other germline mutations are located in the transmembrane domains 2, 3, 5, 6, and 7 of the TSH receptor, whereas no mutation was reported in transmembrane domains 1 and 4 to date. Here we report the first family with a constitutively active TSHR mutation in transmembrane domain 1 resulting in a substitution of the conserved Gly 431 for Ser. This mutation was found in the investigated patient, his father, and the paternal grandmother. As known from other familial cases of nonautoimmune hyperthyroidism, the age of onset of the disease was variable, ranging from early childhood in the patient and his father to adolescence in the grandmother. Functional characterization of this mutation showed a constitutive activation of the G s / adenylyl cyclase system. Moreover, this germline mutation also activates the G q/11 /phospholipase C pathway. T HE TSH RECEPTOR (TSHR) belongs to the subfamily of glycoprotein hormone receptors, members of the large superfamily of G protein-coupled receptors (GPCR) (1). Glycoprotein hormone receptors share the common structural feature of a large extracellular domain and a transmembrane domain (TM) consisting of seven membrane-spanning segments connected by three intracellular and three extracellular loops. Mutations leading to constitutive receptor activation were first detected in the transmembrane receptor core clustering in TM6 (2, 3). Activating germline mutations of the TSHR gene cause rarely occurring, nonautoimmune sporadic congenital hyperthyroidism (4 -9) or familial nonautoimmune hyperthyroidism (10 -15). Most gain of function mutations are located in TM2, 3, 5, 6, and 7 and at a single amino acid position (Ser 281 ) within the extracellular domain (16). The functional consequence of these mutations is a ligand-independent activation of the G s /adenylyl cyclase system, whereas the G q/11 /phospholipase C system appears to remain unaffected. To date only a few somatic TSHR mutations found in toxic thyroid nodules are also able to constitutively activate both the G s /adenylyl cyclase and the G q/11 /phospholipase C pathways (17).
T HE TSH RECEPTOR (TSHR) belongs to the subfamily of glycoprotein hormone receptors, members of the large superfamily of G protein-coupled receptors (GPCR) (1) . Glycoprotein hormone receptors share the common structural feature of a large extracellular domain and a transmembrane domain (TM) consisting of seven membrane-spanning segments connected by three intracellular and three extracellular loops. Mutations leading to constitutive receptor activation were first detected in the transmembrane receptor core clustering in TM6 (2, 3) . Activating germline mutations of the TSHR gene cause rarely occurring, nonautoimmune sporadic congenital hyperthyroidism (4 -9) or familial nonautoimmune hyperthyroidism (10 -15) . Most gain of function mutations are located in TM2, 3, 5, 6 , and 7 and at a single amino acid position (Ser 281 ) within the extracellular domain (16) . The functional consequence of these mutations is a ligand-independent activation of the G s /adenylyl cyclase system, whereas the G q/11 /phospholipase C system appears to remain unaffected. To date only a few somatic TSHR mutations found in toxic thyroid nodules are also able to constitutively activate both the G s /adenylyl cyclase and the G q/11 /phospholipase C pathways (17) .
In this study we report the first activating TSHR mutation located in TM1 identified in a patient, his father, and grandmother, all suffering from nonautoimmune hyperthyroidism. The missense mutation leads to the substitution of the highly conserved Gly 431 residue to Ser, activating both the G s /adenylyl cyclase system and the phospholipase C pathway in a ligand-independent manner.
Case Report
The propositus is a Caucasian male. He was born at 36 wk gestation, with a birth weight of 2500 g, without complication. Because of a strong family history of hyperthyroidism, thyroid hormone levels were analyzed annually by the primary care physician. These were first noted to be abnormal at the age of 3 yr (Table 1) . The patient had been experiencing sleep difficulties, hyperactive behavior, and a voracious appetite with little weight gain, but no temperature intolerance or bowel movement disturbances were observed. A 99m Tc thyroid scan showed a symmetrical and homogeneously enlarged gland without nodules and mild increased trapping of isotope. The thyroid gland was mildly and symmetrically enlarged without nodules, with an audible bruit over the right lobe. Although his eyes were mildly prominent, magnetic resonance imaging studies did not confirm an exophAbbreviations: bTSH, Bovine TSH; E max , hormone-stimulated cAMP formation; GPCR, G protein-coupled receptors; IP, inositolphosphate; PTU, propylthiouracil; TM, transmembrane domain; TSHR, TSH receptor; WT, wild-type.
thalmus. Medical treatment was started with propylthiouracil (PTU; 25 mg, three times daily) at the age of 3 3/12 yr, and the dose was adjusted over the ensuing months ( Table 1 ). The following history was complicated by increasing difficulties with hyperactive behavior, tremor, sleeping difficulties, and enuresis. Because of persistence of symptoms despite increasing doses of PTU (150 mg/d) and an increase in thyroid hormone levels, he underwent total thyroidectomy at age 7 9/12 yr. The pathology report showed a thyroid gland with hyperplastic features. l-T 4 replacement therapy was initiated and resulted in euthyroidism and resolution of behavioral abnormalities.
The patient's father was diagnosed as hyperthyroid at 4 yr of age. He had a history of difficult sleeping since the age of 2 yr and was reported to have a tremor of the hands, decreased attention span, occasional rapid heart beat, and prominent appearance of his eyes. Treatment was initiated with PTU, which he took intermittently for 3 yr at a dose between 25-50 mg, three times daily. Because of an exacerbation of hyperthyroidism, he underwent subtotal thyroidectomy at 7 6/12 yr of age. The pathology report showed sections of thyroid gland with large follicles. Subsequently he remained euthyroid.
The paternal grandmother developed hyperthyroidism in adolescence and underwent subtotal thyroidectomy at 15 yr of age. At the time of the present study she was receiving thyroid hormone replacement therapy and had had a unilateral goiter for the past 14 yr, surveyed by biopsies that were reported to be benign. She is clinically euthyroid. There is no evidence of thyroid disease on the maternal side of the family.
All clinical investigation and genetic analyses were conducted in accordance with the guidelines proposed in the Declaration of Helsinki, and informed consent was obtained from all family members.
Materials and Methods
Thyroid hormone and TSH levels were determined with Abbott Laboratories IMX kits (Ashland, OH). TSHR antibodies were assayed with the Mayo Laboratory kit (Rochester, MN).
Genomic DNA was prepared from peripheral white blood cells using a commercial kit (Blood Amp kit, QIAGEN, Hilden, Germany). Exons 1-10 of the TSHR gene were amplified with primers previously described (18) . Sequencing reactions were performed with BigDye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer Corp., Weiterstadt, Germany) and were analyzed with an automatic sequencer (ABI 373, PE Applied Biosystems, Foster City, CA).
For restriction enzyme analysis a PCR fragment was amplified using a sense primer (5Ј-GAA TCC TTG AGT CCT TGA TGT G-3Ј) and an antisense primer (5Ј-TGG CAT GGT TGT AGT ACT CA-3Ј). Restriction analyses were performed with DdeI at 37 C for 1 h, and products were separated on a 2% agarose gel.
The TSHR mutation (G431S) identified, as well as TSHR-G431A and TSHR-G431C, were generated using standard mutagenesis techniques. Mutant fragments were inserted by replacing an MscI/BstEII fragment within the pcDps-hTSHR. The correctness of the mutant was verified by restriction analysis and direct sequencing.
To functionally characterize the mutant TSHRs COS-7 cells were transiently transfected, and cAMP accumulation, inositolphosphate (IP) formation, and [
125 I]bovine TSH ([ 125 I]bTSH) binding assays were performed as described previously (19) .
Results and Discussion
Familial nonautoimmune hyperthyroidism is a very rare disease. To date nine families have been identified harboring constitutively activating TSHR mutations causing the disease. All naturally occurring activating TSHR mutations found were located in the extracellular domain (Ser 281 ) or in the TM core, with a prevalence in TM6 and TM7 as well as in the third intracellular loop (4 -15, 17) , but no mutation has yet been identified in TM1 and TM4.
Herein we describe a family with nonautoimmune hyperthyroidism. Direct sequencing of all PCR-amplified exons led to identification of a heterozygous G to A transition in exon 10 at codon position 431. This mutation resulted in the substitution of a highly conserved glycine residue to serine (Gly 431 Ser) in TM1 (Fig. 1C) . The mutation creates a new restriction site for DdeI (Fig. 1B) . Restriction of the PCR fragment amplified from the mother's genomic DNA showed a wild-type (WT) pattern, whereas the father could be identified as a heterozygous carrier of the mutation. Repeated amplification and digestion of the grand- mother's PCR fragment revealed only a weak 168-bp band (see Fig. 1B ). This indicates that the grandmother is probably not a heterozygous carrier of the mutation, but most likely presents a mosaicism of the altered TSHR gene. Sequencing of exon 10 confirmed the heterozygous state for the G431S mutation in the patient and the father, whereas sequencing of the grandmother's fragment showed only a very small A wave under the WT G wave (see Fig. 1C ). Corresponding results were obtained by sequencing the complementary strand. This finding suggests a mosaicism and unveiled the grandmother as potential carrier for this mutation. Unfortunately, the presence of a grandmaternal mosaicism could not be supported or verified further by investigations of other tissue (fibroblasts and hair follicles) and material from other relatives because of the unavailability of further material. In accordance with other reports (10, 14) , the onset of disease in this family ranged from early childhood in the patient and his father to adolescence in the patient's grandmother. However, in this family the later onset of disease in the grandmother may be caused by mosaicism rather than by heterozygosity. For functional characterization of the novel TSHR mutation (TSHR-G431S), COS-7 cells were transiently transfected with the WT TSHR and TSHR-G431S. Basal and hormone-stimulated cAMP and IP3 levels were investigated, and [ 125 I]bTSH binding studies were performed. Expression of the mutant receptor resulted in a greater basal cAMP accumulation compared with the WT-TSHR ( Fig. 2A) . Hormone-stimulated cAMP formation (E max ) found for TSHR-G431S was more pronounced than that after WT-TSHR expression. To ensure that the increase in basal cAMP accumulation of TSHR-G431S was not due to a higher receptor level at the cell surface, TSHR-G431S was diluted 1:2 with the m3 muscarinic receptor. This results in a reduction of the E max value below the level of WT-TSHR-expressing cells. The basal cAMP accumulation mediated by the diluted mutant receptor remained elevated (see Fig. 2A ), indicating strong basal activity. Basal IP formation mediated by TSHR-G431S was slightly, but significantly, higher (by t test, P Ͻ 0.001) compared with that mediated by the WT-TSHR (Fig. 2B) . As expected from the cAMP accumulation assay [
125 I]TSH binding of TSHR-G431S revealed a higher level of expression (Table 2) , whereas the affinity of TSH to the mutated receptor remained unaffected (see Table 2 ).
Investigation of naturally occurring mutations in GPCRs provide important structural information of receptor activation or inactivation. Gly 431 is conserved not only in the glycoprotein hormone receptors of different species, but also in many family 1 GPCRs (GPCR database; http://www.gpcr.org/7tm/). Next, we asked whether the observed constitutive activity of TSHR-G431S is specifically due to a Ser substitution of Gly 431 . Thus, this position was substituted by Cys (almost same size of the side chain as Ser) and Ala (almost the same size of the side-chain, but no hydrogen bonds possible). Both mutant TSHRs, TSHR-G431C and TSHR-G431A, showed elevated basal cAMP levels, but in contrast to G431S, E max values were comparable to those found with the WT-TSHR. TSH-mediated IP formation was identical in WT-TSHR and both mutant receptors (see Fig. 2 ). Our preliminary data concerning this specific position indicate that only a very small amino acid residue, such as Gly, is tolerated at position 431.
The only activating mutation in TM1 within the glycoprotein hormone receptor family was reported in a patient suffering from male-limited precocious puberty (20) . A constitutively activating mutation of the LH receptor Ala 373 Val . B, To trace the mutation to other family members, a 575-bp fragment was amplified, digested with DdeI, and separated on a 2% agarose gel. In the presence of the mutation, the 575-bp fragment is cut into fragments of 368, 207, and 168 bp. The 168-bp fragment is missing in the absence of the mutation. C, Sequencing of one fragment of exon 10 revealed a heterozygous mutation in the patient and the father (not shown) at nucleotide position 1291, where a G is substituted by an A, resulting in a change of Gly 431 to Ser. Sequencing of the PCR product of the grandmother revealed only a very small A wave (arrow) under the G.
was described corresponding to position 428 in the TSHR, which is approximately one ␣-helical turn above, as seen from the cell interior, very close to that in the TSHR described here. Gromoll and co-workers (20) speculated that due to the high degree of conservation in this receptor region throughout species, this receptor region may have an important role in maintaining receptor quiescence.
In the present study we identify the first constitutively activating mutation in TM1 of the human TSHR, indicating that activating mutations can be distributed over the entire TM region. Functional studies that are extended to other signal transduction pathways beside the G s /adenylyl cyclase system may also help in understanding the structure-function relationship. COS-7 cells were transfected with the wild-type or TSHR mutants. EC 50 and E max values were obtained from concentration-response curves (from 0.01-1000 mU bTSH/ml), using the computer program GraphPad PRISM. Data are the mean Ϯ SEM of three independent experiments performed in duplicate. K i values were obtained from displacement studies (from 0.01-1000 mU bTSH/ml), using the computer program LIGAND. Experiments were carried out in three independent experiments performed in duplicate.
ND, Not determined.
